ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
01/01/2026 01:55 PM • Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered after Alvotech announced on November 2, 2025, that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and an additional 4% on November 4, 2025. Investors who purchased Alvotech securities may be eligible for compensation through a class action lawsuit.
ALVO - The company faces a significant stock price decline (34% on November 3, 2025) following FDA rejection of its AVT05 biologics license application due to manufacturing facility deficiencies. A securities class action investigation has been initiated, indicating potential investor harm and allegations of misleading disclosures.
Investing.com • Leo Miller